SERB Deal Lifts Hansa Biopharma's Q3 Revenue to SEK 143 Million

Your call?🐂 Bullish🐻 Bearish

License revenue included part of a €110 million upfront payment for Idefirix rights in Europe and the MENA region. Basic and diluted earnings per share were negative SEK 1.75.